Helix BioMedix Inc banner

Helix BioMedix Inc
OTC:HXBM

Watchlist Manager
Helix BioMedix Inc Logo
Helix BioMedix Inc
OTC:HXBM
Watchlist
Price: 1 USD Market Closed
Market Cap: $224.7k

Helix BioMedix Inc
Investor Relations

Helix BioMedix, Inc. is a biopharmaceutical company, which focuses on drug development for treatment of rare dermatological diseases, such as Xeroderma Pigmentosum. The company is headquartered in Bothell, Washington and currently employs 8 full-time employees. The company went IPO on 2000-07-25. The firm is focused on drug development for treatment of rare dermatological diseases. The firm's research and development (R&D) consists of a proprietary library of patented bioactive peptides based on the body’s innate immunity. The firm is focused on developing HB4208 for treatment of the rare disease Xeroderma Pigmentosum (XP). HB4208 is a polypeptide DNA Damage Response (DDR) enzyme that is based on cellular repair pathways. HB4208 is in the preclinical development Phase. The firm is also engaged in identifying the precise peptides needed to stimulate cellular processes and control cell wall defense. Using the specific amino acid sequence for the desired activity, the Company's peptides work with targeted precision to provide optimal skin enhancing results in cosmeceutical and over the counter (OTC) formulations. Its peptides include Oligopeptide-10, Palmitoyl Hexapeptide-14 and others.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Ms. Robin L. Carmichael
President, CEO & Director
No Bio Available
Kelly Forsythe
Associate Director of Marketing
No Bio Available

Contacts

Address
WASHINGTON
Bothell
22121 17th Ave SE Ste 112
Contacts
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett